Products to be launched at AARC International Respiratory Congress in Orlando, Florida
NEW YORK, Nov. 29 /PRNewswire-First Call/ -- SPO Medical Inc.
(OTC Bulletin Board: SPOM), a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices, will be demonstrating its new PulseOx 6000(TM) and PulseOx 6100(TM) in the US market at the 53rd Annual International Respiratory Congress of the American Association for Respiratory Care (AARC) in Orlando, Florida (December 1-3,2007).
The PulseOx 6000(TM) (finger device) and PulseOx 6100(TM) (hand-held device) have both been designed for use by medical professionals, hospitals and managed care facilities. Both the PulseOx 6000(TM) and PulseOx 6100(TM)use patented Reflective Pulse Oximetry (RPO) technology for accurate and reliable measurements of blood oxygen saturation and heart rate, and include the SPO Medical new AutoSpot(TM) technology for patients suffering low perfusion. Both products have regulatory clearance for marketing in the United States and are planned to become commercially available in the first quarter of 2008.
"We are delighted to introduce the PulseOx 6000(TM) and PulseOx 6100(TM)for the first time in the US at AARC's International Respiratory Congress, the most prestigious gathering of respiratory care professionals," said Michael Braunold, President and Chief Executive Officer of SPO Medical. "Our business strategy and product achievements to date are a testament to our continued success in delivering new life-saving and life-enhancing products to the respiratory marketplace."
AARC, a professional membership association of respiratory therapists, focuses primarily on respiratory therapy education and research. Its goals arête ensure that respiratory patients receive safe and effective care from qualified professionals and to benefit respiratory health care providers. Arc’s International Respiratory Congress is a one-stop destination for the latest scientific evidence on the care and treatment of respiratory conditions and the newest and most advanced respiratory technology.
SPO Medical will be located at booth #237 and their executives will be available to answer questions at the AARC International Respiratory Congress.
About SPO Medical:
SPO Medical (SPOM) a leading developer of biosensor and microprocessor technologies for use in portable monitoring devices to capture life-saving and life-enhancing information within four key markets: medical care; home and remote-care; sports and wellness; and safety and security. Its patented technology uses information gathered from the reflectance of light on the human blood stream, in a non-invasive manner, to monitor key vital signs. The Company distributes its products through a network of distributors and also licenses its technologies to appropriate client corporations for commercialization and distribution. For more information, visitwww.spomedical.com.
This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections about our business and our industry, and that reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including but not limited to, changes in economic conditions generally and the medical devices market specifically, changes in technology, legislative or regulatory changes that affect us, the availability of working capital, changes in costs and the availability of goods and services, the introduction of competing products, planned product launches, changes in our operating strategy or development plans, our ability to attract and retain qualified personnel, and the risks and uncertainties discussed under the heading "Risk Factors" in Item1 of our Annual Report on Form 10-KSB for the fiscal year ended December 31,2006. We undertake no obligation to revise or update any forward-looking statement for any reason. SOURCE SPO Medical Inc. Michael Braunold, CEO of SPO Medical Inc., 011-972-9-7643570,email@example.com; or Christine J. Petraglia of Seventh Circle Consulting for SPO Medical Inc., +1-646-354-8886, firstname.lastname@example.org